Lonza Group AG LONZA GROUP ORD SHS | 582.80 / -0.78% |
Date/Time | 01/18 / 19:00 |
Chg. / Chg.(%) | -4.60 / -0.78% |
Bid | 297.60 / 5000 |
Ask | 312.80 / 5000 |
Open | 586.80 |
Previous Close | 587.40 |
High | 589.40 |
Low | 580.60 |
Volume [CHF] | 4,196,930.75 |
Volume [Units] | 14,235 |
Price fixings | 89 |
ISIN | CH0013841017 |
Security | 0QNO |
Exchange | London International |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 582.80 | ![]() |
192,337 |
London Inter.. | 582.80 | ![]() |
14,235 |
Lang & Schwa.. | 541.600 | ![]() |
|
Nasdaq Other.. | 663.0400 | ![]() |
103 |
Mexico | 13,159.94 | ![]() |
270 |
Cboe Europe .. | 328.30 | 47,868 | |
Turquoise | 328.30 | ![]() |
18,782 |
Cboe Europe .. | 328.00 | 12,923 | |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire - Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
01/08/2021 / 13:00 - GlobeNewswire - Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
12/23/2020 / 14:00 - GlobeNewswire - Recro Announces Executive Changes
12/16/2020 / 13:00 - GlobeNewswire - Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
12/07/2020 / 22:05 - GlobeNewswire